Edición genética con CRISPR: del deseo a la realidad · 14 reference:...
Transcript of Edición genética con CRISPR: del deseo a la realidad · 14 reference:...
1
Edición genética con CRISPR: del deseo a la realidad
@LluisMontoliuCNB-CSIC y CIBERER-ISCIII
2
www.albinismo.es
3
He Jiankui (Shenzhen, China)
Monday, 26 November 2018
4
5
Definitions
• Moral/morality: what people believe to be right/good or wrong/bad. Set of codes of conductadopted governing human behavior.
• Ethics: is a critical reflection about morality. Providesa systematic way to work through dilemas to determine the best course of action amongconflicting choices, a generalized conceptual framework for decision making.
• Bioethics: the study of ethical issues arising fromhealth care, in biological and medical sciences.
Basic principles in Bioethics
• Principle of non‐maleficence
• Principle of beneficence
• Principle of respect for autonomy
• Principle of justice
6
Genome editing tools (CRISPR)
• Great tools for basic research
• Have become instrumental to investigate on human congenitaldiseases
• We do not control the output
• Still associated with uncertainty
• Not yet ready for clinical use (unsafe forin vivo, potentially useful for ex-vivo)
Mojica and Montoliu, Trends in Microbiology 2016
Prokaryotes Eukaryotes
Francis J. M. MojicaUniversity of Alicante (Spain)
1993 First CRISPR described in archaea2001 Coins the name CRISPR2005 CRISPR as inmune systems2009 Coins the name PAM
7
Mojica and Montoliu, Trends in Microbiology 2016
Prokaryotes Eukaryotes
Fixing the DSB: NHEJ vs HDR
8
The CRISPR-CasSystem in 2012
The CRISPR-CasSystem in 2019
RNP
9
Off-target effects
On-targeteffects
Mosaicism
HDR isnot the
preferredrepairingpathway
Related toCRISPR
Unrelated toCRISPR
Current limitations of CRISPR-Cas9 tools
10
We have not foundoff-target sites withaltered sequences in genome-edited mice
Confirmed by NGS
What about off-targets?
Mostly observed in vitro
Seruggia et al. 2015 NAR
11
A1 B1
A2
A10
B2
B10
A1 – AAGTTAGGATTAGAGGATCCATACCCTAGCGG||||||||||||||||||||||||||||||||
B1 - AAGTTAGGATTAGAGGATCCATACCCTAGCGG
A10 – AAGCTAGGATAAGAGGATCCATACCCTACCGG|*|*||||||*|||*|||||*|||||||*|||
B10 - ATGTTAGGATTAGACGATCCTTACCCTAGCGG
Spontaneous Mutations + Genetic Drift Divergent Mouse Subcolonies
Montoliu & Whitelaw, Transgenic Res. 2018
• Founder animals are nearly always complexmosaic
• Many different allelescan be present
• Not all of them mighttransmit throughgermline
One 8-cell embryo = 16 possible alleles
On-targets: the real problem
12
Albinism Facts
Genetic condition, recessive trait1:17.000 (rare disease)
Visually impaired, lack foveaReduced visual acuityAbnormal quiasmatic connectionsPhotofobia, Nystagmus
Several types, syndromic or notMost (but not all) associated withhypopigmentation in skin & eyes, OCA (or eyes only, OA)
Do not tan, sunburnCan have increased skin cancerGenetically heterogeneousAt least 20 genes associated
Mouse Human Albinism Mutations (HGMD)Tyr TYR OCA1 395Oca2 OCA2 OCA2 235Tyrp1 TYRP1 OCA3 37Slc45a2 SLC45A2 OCA4 116?? 4q24 OCA5 1slc24A5 SLC24A5 OCA6 13Lrmda LRMDA OCA7 8Gpr143 GPR143 OA1 148Sl38a8 SLC38A8 FHONDA 11Lyst LYST CHS1 88Hps1 HPS1 HPS1 45Ap3b1 AP3B1 HPS2 31Hps3 HPS3 HPS3 14Hps4 HPS4 HPS4 18Hps5 HPS5 HPS5 27Hps6 HPS6 HPS6 26Dtnbp1 DTNBP1 HPS7 3Bloc1s3 BLOC1S3 HPS8 2Bloc1s6 BLOC1S6 HPS9 1Ap3d1 AP3D1 HPS10 2
There are at least 20 genes associated with albinism
Montoliu et al. PCMR 2014; Montoliu & Marks PCMR 2016
mel
ano
cyte
sM
elan
oso
mes
/lyso
som
es
HGMD ® 2017.4
13
Diversity of pigmentations but all are visually impaired
OCA1OCA4HPS
OCA4 avatar mouse models
14
Reference: AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCACGGTAGGGTTGATTTCAGGAAATGTAAB9040.1 AACATTGGAGGAGCTGC ACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAG-----------GTAGGGTTGATTTCAGGAAATGTAAB9040.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGGTAGGTAGG-TTGATTTCAGGAAATGTAAB9040.3 AACACTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAG-----------GTAGGGTTGATTTCAGGAAATGTAAB9040.4 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGC-----AGGGTTGATTTCAGGAAATGTAAB9040.5 CAAGCTCCTGCCCCACTTTCAAAGCTGTACTGAACTGCAGTTTCTTCTCCACCCAGATTCCTGCAAGACCTTGCACCGGGG------------(437bp)------------------B9040.6 --------------------------------------------(561bp)-------------------------------------------------------------------B9041.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCTGTTACCTAGGGTTGATTTCAGGAAATGB9041.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAAC--------AGGGTTGATTTCAGGAAATGTAAB9041.3 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACA----GGTAGGGTTGATTTCAGGAAGTGTAAB9041.4 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACG----GGTAGGGTTGATTTCAGGAAATGTAAB9041.5 AACATTGGAGGAGCTGCCACTGCTATTTGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACA----GGTAGGGTTGATTTCAGGAAATGTAAB9042.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCACGGTAGGGTTGATTTCAGGAAATGTAAB9042.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAAT---------------GGTAGGGTTGATTTCAGGAAATGTAAB9042.3 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAA-TGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCACGGTAGGGTTGATTTCAGGAAATGTAAB9042.4 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAAT---------------GGTAGGGTTGATTTCAGGAAGTGTAAB9043.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAAT---------------GGTAGGGTTGATTTCAGGAAGTGTAAB9043.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCACACTGGTAGGGTTGATTTCAGGAAGTGB9043.3 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTCCCAATCAGGAGTTGAGAAAAAT---------------GGTAGGGTTGATTTCAGGAAGTGTAAB9043.4 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGATAGACATGTCGAGGA------(134bp)--------------------B9044.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAAT---------------GGTAGGGTTGATTTCAGGAAATGTAAB9044.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCGATCAGGAGTTGAGAAAAATGGTAGGTAAC--------AGGGTTGATTTCAGGAAATGTAAB9045.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTTGTTTAT-------------------------------CAAGGTAGGGTTGATTTCAGGAAATGTAAB9045.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAAT--------------------GGTTGATTTCAGGAAATGTAAB9045.3 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTTGTTTAT-------------------------------CAAGGTAGGGTTGATTTCGGGAAATGTAAB9046.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCACCTAGGTAGGGTTGATTTCAGGAAATGB9046.2 AACATTG--------------------------------(87bp)-------------------------------------------------TAGGGTTGATTTCAGGAAATGTAAB9046.3 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCAATGGTAGGGTTGATTTCAGGAAATGTAB9046.4 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCACCTAGGTAGGGTTGATTACAGGAAATGB9060.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACA----GGTAGGGTTGATTTCAGGAAATGTAAB9060.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAGATGGTAGGTAACA----GGTAGGGTTGATTTCAGGAAATGTAAB9060.2 GACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACA----GGTAGGGTTGATTTCAGGAAATGTAAB9060.3 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCT-------GTTGATTTCAGGAAATGTAAB9060.4 AACATCGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACA----GGTAGGGTTGATTTCAGGAAATGTAAB9064.1 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCAAAAATGGTAGGTAGGGTTGATTTCAGGB9064.2 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTA-----------GGTAGGGTTGATTTCAGGAAATGTAAB9064.3 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAGTGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGCAAAAATGGTAGGTAGGGTTGATTTCAGGB9064.4 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCAGGAGTTGAGAAAAATGGTAGGTAACAGC-----AGGGTTGATTTCAGGAAATGTAAB9064.5 AACATTGGAGGAGCTGCCACTGCTATTGGGGACCCACCAAATGTTATCATTGTTTCCAATCA------------------------------GGTAGGGTTGATTTCAGGAAATGTAA
sgRNA‐A476
ssDNA
Multiple alleles present in CRISPR founder gene-edited mice
***
*
* *
***
**
* * *
15
***
*
* *
***
**
* * *
Doudna & Charpentier (2014) Science
CRISPR-Cas is the future
16
IN VIVO EX VIVO
Ex-vivo immunotherapy: targeting PD-1 gene with CRISPR tools
17
Ex-vivo CRISPR targeting of BCL11A enhancer forSickle cell anemia and beta-thalassemia
Bauer Lab (Dana Farber-Boston Children’s)
First ex-vivo CRISPR therapyapproved in Europe
Associated Press, 15 Nov 2017
• UCSF Benioff Children's Hospital in Oakland, California
• IV injection of viral particles with ZFNs• Approved by NIH• Sangamo• Hunter’s syndrome (I2S gene)
Mucopolysaccharidosis II (MPS II)• Lysosomal storage disease• Injected on 13 Nov 2017• No therapeutic effect seen• No toxicity detected
First genome editing (driven by ZFN) somatic gene therapy in a patientIN VIVO
IN VIVO
18
CRISPR‐Cas9 and in vivo somatic gene therapy
Amoasii et al. Science 20183-92% correction
Increasing number of animal models of raremonogenic diseases corrected via CRISPR
• Duchenne muscular distrophy (DMD)• Ornithine transcarbamylase (OTC) deficiency• Hereditary tyrosinemia I (FAH deficiency)• Congenital cataract (CRYGC)• Chronic granulomatous disease (CGD)• Retinitis pigmentosa (RP)• Leber congenital amaurosis (LCA)• Hungtinton Disease (HD)• …• Alsomany iPS cells models correcting gene mutations via
CRISPR strategies
Preclinical animal models
19
Cas9: Bang Wong, Broad Institute of Harvard and MIT, Cambridge, MA
• Cas9 antibodiesfound in human serum
• Anti‐Cas9 T lymphocites found in human blood
• 79% individuals haveantibodies againstSaCas9
• 65% individuals haveantibodies againstSpCas9
• 46% individuals haveanti‐Cas9 T cells
• Immunosupression oralternative Cas proteins
5 Jan 2018 – 28 Jan 2019 Nature Med.
Cas9Streptococcus pyogenesStaphylococcus aureus
Human retina
Correcting a point mutation in CEP290 gene with NHEJ CRISPR
Leber’s congenital amaurosis type 10
In vivoDecember 2018
20
Correcting a point mutation in CEP290 gene with NHEJ CRISPR
Leber’s congenital amaurosis type 10
December 2018
CRISPR and human embryos
• Several studies from China using 3n/2n embryos
• Many different alleles are produced
• Most edited embryos are mosaic
• Anticipate potential off-target effects
• Need for careful risk/benefit analysis
• Consider alternative technologies (PGD: preimplantationgenetic diagnosis)
• Need to be cautious before applying
• Poses Ethics dilemas and contravenes current norms
(art 13 and art. 18, Asturias Convention, 1997)
21
2 August 2017
CRISPR-Cas9
Large deletions after DSB induced by CRISPR-Cas9
Kosicki et al. 2018 Nature Biotech.Adikusuma et al. 2018 Nature Comm.
22
*
♀
♂
*CRISPR-Cas9
Alternative interpretations for Mitalipov experiments
Gene therapy on human embryoswith CRISPR
Illegal, Unnecessary & Unwise
23
20 September 2017
CRISPR Oct4 in mouse embryos Blastocyst OK, related genes alteredCRISPR Oct4 in human embryos Blastocyst compromised, related genes OK
Gene research on human embryoswith CRISPR
Legal, Necessary & Wise
24
He Jiankui (Shenzhen, China)
7 couples 31 embryos 2 pregnancies 1 delivered (twin girls: Lulu y Nana) +1
Gene improvement on human embryoswith CRISPR
Illegal, Unnecessary, Unwise& Irresponsible
25
26
He Jiankui (Shenzhen, China)
The red lines crossed
• Without knowledge, without authorization, withoutethics review, without ethics approval, secrecy
• Implanting genome-edited human embryos and lettingthem develop to term (two newborns)
• Genome-editing on unaffected human embryos not fortherapeutical purposes but for enhancement, addingthem a new trait (resistance to HIV infection)
He Jiankui (Shenzhen, China)
Technical issues
• The CCR5 gene
• Off-target mutations
• Mosaicism
• Uncertainty / unpredictable risks
27
The CCR5 gene / co‐receptor
• Used by HIV to access T lymphocytes
• Has numerous other functions in theimmune system
• A deletion of 32 bp was found in 1996 in people resistant to HIV infection(CCR5‐Δ32)
• Loss of CCR5 function associated with:
• Increased infectivity by flavivirus like West Nile virus and thosecausing Dengue and Yellow Fewer
• Increased mortality after infectionby Influenza virus
28
Jing‐Bao Nie
29
He Jiankui (Shenzhen, China)
The lessons
• This should have NOT occurred
• But this was likely to occur, sooner or later
• Many reports and recommendations published
• No universal codes / rules / laws yet available
• Need to promote global governance rules
Numerous reports on genome editing
• US NAS/NAM
• EASAC
• INSERM
• EGE
• ASHG
• Deutscher Ethikrat
• Fed. Eur. Acad. Med.
• HUGO
• Leopoldina
• Schweizer Ethikrat
• Nuffield Bioethics Council
• …
30
NAS‐2017 (USA)
• Clinical trials using heritable genome editing should be permitted only within a robust and effective regulatory framework that encompasses:
– the absence of reasonable alternatives;
– restriction to preventing a serious disease or condition;
– restriction to editing genes that have been convincingly demonstrated to cause or to strongly predispose to that disease or condition;
– restriction to converting such genes to versions that are prevalent in the population and are known to be associated with ordinary health with little or no evidence of adverse effects;
– the availability of credible preclinical and/or clinical data on risks and potential health benefits of the procedures;
– ongoing, rigorous oversight during clinical trials of the effects of the procedure on the health and safety of the research participants;
– comprehensive plans for long-term, multigenerational followup that still respect personal autonomy;
– maximum transparency consistent with patient privacy;
– continued reassessment of both health and societal benefits and risks, with broad ongoing participation and input by the public; and
– reliable oversight mechanisms to prevent extension to uses other than preventing a serious disease or condition.
31
NCB‐2018 (UK)
• Reproductive cells that have been subject to heritable genome editing interventions should only be used for purposes that are consistent with the welfare of the future person.
• The use of heritable genome editing interventions would only be ethically acceptable if carried out in accordance with principles of social justice and solidarity.
• If heritable genome editing were to become feasible, those whose genomes have been edited should be entitled to the same enjoyment of human rights as everyone else.
Initial pre‐ARRIGE 2017 publications in Nature and Transgenic Research
Nature (2017) Hirsch et al.
32
Association for Responsible Research and Innovation in Genome Editing
ARRIGE Kick‐Off meeting, Paris, 23 March 2018
ARRIGE featuredin Science
33
ARRIGE featured in NatureBiotechnology
ARRIGE presented in The CRISPR Journal
34
http://arrige.org• Fostering the development of genome editing technologies within a safe and ethical framework for individuals and for our societies.
• Fostering an inclusive debate with a risk‐management approach, taking into account the human, environmental, animal and economic issues
• Promoting a global governance of genome editing through a comprehensive setting for all stakeholders
• Creating an ethical tool box and informal guidance for genome editing technology users, regulators, governance and the civil society at large
• Developing a robust particular reflection on the role of the lay public in this debate and the necessity for improved public engagement
Aims:
35
Genome editing (CRISPR)
• We should not be using genomeediting on human beings until thesetechniques are deemed safe and effective, with precise therapeutic applications justified after a broad and open debate.
UNESCO is the United Nations Educational, Scientific and Cultural Organization
36
Association for Responsible Research and Innovation in Genome Editing
https://arrige.org
a
Marion AbecassisBernard BaertschiHervé ChneiweissFrançois HirschPierre JouannetChristine LemaitreJennifer MerchantLluis MontoliuCyril Sarrauste de Menthière
37
Lluís Montoliu’s Lab at CNB
http://www.cnb.csic.es/~montoliu
www.cnb.csic.es/~montoliu/CRISPR/
Google CNB + CRISPR
Para más información sobre CRISPR
38